Business UpdateJun 9, 2026, 07:36 AM
Incannex Initiates Research Coverage by AGP; BUY Rating, $18 Price Target
AI Summary
Incannex Healthcare Inc. announced that Alliance Global Partners (AGP) has initiated equity research coverage of the company. The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex's clinical pipeline, development strategy, market opportunities, and future growth prospects. AGP assigned a "BUY" rating with a price target of US$18.00 per share, which Incannex believes will expand investor awareness of its clinical programs, including IHL-42X and PSX-001.
Key Highlights
- Alliance Global Partners initiated equity research coverage on Incannex Healthcare Inc.
- AGP assigned a "BUY" rating to Incannex Healthcare Inc.
- AGP set a price target of US$18.00 per share for Incannex Healthcare Inc.
- The research report covers Incannex's lead obstructive sleep apnea program, IHL-42X.
- The report also discusses the synthetic psilocybin program, PSX-001, for generalized anxiety disorder.
Price Impact
More from IXHL